Table 1.
Basic characteristics of 17 prospective randomised trials reporting data bone marrow sparing chemoradiotherapy in the treatment of cervical cancer patients.
| 1st author | Year | Language | Country | # cases | Treatment years | Median age [years] | Median FU [months] | Setting | Brief inclusion criteria |
|---|---|---|---|---|---|---|---|---|---|
| Du C. [1] | 2013 | Chinese | China | 40 | 2011–2012 | 50 | n/a | postoperative | FIGO n/s, age n/s, ECOG 0–2 |
| Zhang D. [5] | 2017 | Chinese | China | 41 | 2016–2017 | 58 | n/a | postoperative | FIGO n/s, age n/s, ECOG 0–2 |
| Luo C. [7] | 2018 | Chinese | China | 102 | 2013–2015 | mean: 50 | n/a | postoperative | FIGO n/s, age n/s, ECOG n/s |
| Sun S. [8] | 2018 | Chinese | China | 40 | 2016–2017 | 50 | 3 | postoperative | FIGO n/s, age n/s, ECOG n/s |
| Fang M. [9] | 2019 | Chinese | China | 78 | 2012–2015 | mean: 50* | n/a | postoperative | FIGO n/s, age n/s, ECOG n/s |
| Xie Y. [12] | 2021 | Chinese | China | 50 | 2018–2020 | mean: 53* | n/a | postoperative | FIGO n/s, age n/s, ECOG n/s |
*estimated based on available data; n/s – not specified; FIGO – disease stage according to The International Federation of Gynecology and Obstetrics; ECOG − Eastern Cooperative Oncology Group performance status; KPS − Karnofsky Performance Scale.